Allan Ramirez, MD
Pulmonary Disease · Louisville, KYNPI 1457389280
Payments from drug & device makers
Across 121 payments — averaging $90.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- PARI Respiratory Equipment, Inc.$2K
- Boehringer Ingelheim$1K
- United Therapeutics Corporation$797
- Pulmonx Corporation$758
- Mylan Specialty L.p.$503
- plus $5K from 27 others
What the payments were for
- Consulting fees$1,50014%
- Food & beverage$9,45886%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 17 | $1,687 |
| PARI Respiratory Equipment, Inc. | 2 | $1,628 |
| Boehringer Ingelheim | 10 | $1,003 |
| United Therapeutics Corporation | 8 | $797 |
| Pulmonx Corporation | 11 | $758 |
| Mylan Specialty L.p. | 7 | $503 |
| Gilead | 4 | $456 |
| Insmed, Inc. | 6 | $376 |
| Nabriva Therapeutics, PLC | 2 | $371 |
| AbbVie | 7 | $339 |
| Astellas Pharma US Inc | 5 | $306 |
| Baxter Healthcare | 6 | $270 |
| Mallinckrodt Hospital Products Inc. | 3 | $265 |
| Veloxis Pharmaceuticals, Inc. | 2 | $242 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $235 |
| Viatris Specialty LLC | 3 | $179 |
| Axogen | 1 | $140 |
| Sanofi | 1 | $133 |
| Vertex | 7 | $129 |
| Boston Scientific | 1 | $124 |
| Actelion Pharmaceuticals US, Inc. | 1 | $120 |
| Regeneron Healthcare Solutions, Inc. | 1 | $120 |
| Bayer | 1 | $120 |
| Advanced Respiratory, Inc | 2 | $105 |
| Shionogi Inc | 1 | $102 |
| Merck | 1 | $95 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $86 |
| Zambon USA Ltd. | 1 | $71 |
| Digestive Care, Inc. | 1 | $69 |
| Chiesi USA, Inc. | 3 | $50 |
| Electromed, Inc. | 1 | $43 |
| CSL Behring | 1 | $27 |
| Genentech USA, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KITABIS PAK$1,628
- FASENRA$945
- TOBI Podhaler$504
- Pulmonx Endobronchial Valve EBV$393
- Xenleta$371
- TEZSPIRE$365
- Envarsus$359
- CRESEMBA$245
- Arikayce$243
- Cayston$241
- LIVTENCITY$235
- ACTHAR$227
- CHARTIS CATHETER$149
- ZEPHYR DELIVERY CATHETER$149
- ZEPHYR ENDOBRONCHIAL VALVE$149
- PULMONX CHARTIS TABLET CONSOLE$149
- AVANCE NERVE GRAFT$140
- WAYRILZ$133
- Hillrom - Vest System Model 105 Home Care$126
- Creon$125
How this compares
$10,965 in reported general payments places this provider in the 70th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 109 | $2,833,589 |
| CreonLipase/Protease/Amylase | 45 | $306,844 |
| CaystonAztreonam Lysine | 17 | $207,207 |
| CresembaIsavuconazonium Sulfate | 25 | $197,407 |
| Fasenra PenBenralizumab | 14 | $80,387 |
| EliquisApixaban | 45 | $47,248 |
| Valganciclovir Hcl | 84 | $46,367 |
| Voriconazole | 24 | $25,228 |
| Sirolimus | 19 | $19,194 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $17,005 |
| Envarsus XrTacrolimus | 13 | $9,323 |
| Tacrolimus | 49 | $8,623 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $7,065 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $6,628 |
| Mycophenolate Mofetil | 44 | $5,785 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| VertexTrikafta | $129 | $2,833,589109 claims |
| AbbVieCreon | $339 | $306,84445 claims |
| GileadCayston | $456 | $207,20717 claims |
| Astellas Pharma US IncCresemba | $306 | $197,40725 claims |
| Boehringer IngelheimCombivent Respimat | $1,003 | $7,06512 claims |
| AstraZenecaSymbicort | $1,687 | $6,62817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Louisville
- John McConnellLouisville$3.5M
- Sally SulimanLouisville$472K
- Mohamed SaadLouisville$440K
- David WinslowLouisville$431K
- Karim El-KershLouisville$379K
- Harold HallerLouisville$369K
- Samantha BaahLouisville$226K
- Lebnan SaadLouisville$105K
- Josephine MeiLouisville$101K
- Tanya WieseLouisville$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.